<DOC>
	<DOCNO>NCT00955968</DOCNO>
	<brief_summary>This study randomize strategy trial conduct among woman receive highly active antiretroviral therapy ( HAART ) pregnancy purpose prevention mother-to-child transmission ( PMTCT ) HIV otherwise meet criterion initiate HAART health . The study design determine whether continuation HAART delivery pregnancy outcome reduces morbidity mortality compare discontinuation re-initiation HAART accord current standard care .</brief_summary>
	<brief_title>IMPAACT 1077HS : Examining Benefits HAART Continuation Postpartum Women</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Women age &gt; 18 year attain minimum age independent consent , define local IRB , willing able provide write informed consent Additionally , sit IRB approval enroll young participant , woman age 1617 year willing able provide write assent whose parent legal guardian willing able provide write informed consent Confirmed HIV infection , document positive result two sample collect different time point prior study entry , use protocolspecified test Documentation hepatitis B surface antibody ( HBsAb ) status hepatitis B surface antigen ( HBsAg ) status ( antibody negative ) within 12 month prior study entry Within 042 day pregnancy outcome Antiretroviral treatment naïve , define &lt; 14 day one antiretroviral agent , prior therapy initiate current pregnancy Receipt least four week HAART prior study entry , least two week must prior pregnancy outcome ( seven consecutive day miss therapy permit ) CD4+ cell count ≥ 400 cells/mm3 specimen obtain within 120 day prior initiation HAART current pregnancy CD4+ cell count ≥ 400 cells/mm3 specimen obtain HAART within 45 day prior study entry The following laboratory value specimen obtain within 45 day prior study entry : Absolute neutrophil count ≥ 750/mm3 Hemoglobin ≥ 7.0 g/dL Platelet count ≥ 50,000/mm3 AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase ≤ 2.5 x ULN Estimated creatinine clearance ≥ 60mL/min within 45 day prior entry use CockcroftGault formula Intent remain current geographical area residence duration study Willingness attend study visit require study Previous participation PROMISE ( P1077 ) Clinical indication HAART include WHO Clinical Stage 3 4 condition , prior current tuberculosis disease ( positive PPD test alone consider exclusionary ) , and/or clinical indication per countryspecific treatment guideline Clinically significant illness condition require systemic treatment and/or hospitalization within 30 day prior study entry Social circumstance , opinion site investigator , would hinder longterm follow Use prohibit medication within 14 day prior study entry ( refer study MOP list prohibit medication ) Current compulsory detention ( involuntary incarceration ) correctional facility , prison , jail legal reason compulsory detention medical facility treatment either psychiatric physical ( e.g. , infectious disease ) illness Currently breastfeed plan breastfeed Current documented conduction heart defect ( specialized assessment rule condition require ; heart murmur alone and/or type 1 seconddegree atrioventricular block ( also know Mobitz I Wenckebach ) consider exclusionary ) Known evidence HBV DNA level &gt; 2000 IU/mL ( approximately 10,000 copies/mL ) presence elevate ( grade 1 high ) ALT ( HBV DNA test require study screen enrollment consider determine whether treatment HBV indicate )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>HIV Infection</keyword>
	<keyword>HAART</keyword>
	<keyword>Maternal Health</keyword>
</DOC>